Reduced treatment-emergent sexual dysfunction as a potential target in the development of new antidepressants

Depression Research and Treatment

Volumn 2013, Issue , 2013, Pages

  Baldwin, David S ^a,b   Palazzo, M Carlotta ^c   Masdrakis, Vasilios G ^d  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^d NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84874634713     PISSN: 20901321     EISSN: 2090133X     Source Type: Journal    
DOI: 10.1155/2013/256841     Document Type: Review

References (75)

1. DeRogatis L. R., Burnett A. L., The epidemiology of sexual dysfunctions. Journal of Sexual Medicine 2008 5 2 289 300 (Pubitemid 351167739)
2. Lewis R. W., Fugl-Meyer K. S., Corona G., Hayes R. D., Laumann E. O., Moreira E. D., Rellini A. H., Segraves T., Definitions/epidemiology/risk factors for sexual dysfunction. Journal of Sexual Medicine 2010 7 4 1598 1607 2-s2.0-77955257328 10.1111/j.1743-6109.2010.01778.x
3. Nicolosi A., Laumann E. O., Glasser D. B., Moreira E. D., Paik A., Gingell C., Sexual behavior and sexual dysfunctions after age 40: the global study of sexual attitudes and behaviors. Urology 2004 64 5 991 997 2-s2.0-7744221407 10.1016/j.urology.2004.06.055 (Pubitemid 39469520)
4. Rosen R. O., Fisher W. A., Eardley I., Niederberger C., Nadel A., Sand M., The multinational Men's Attitudes to Life Events and Sexuality (MALES) study: I. Prevalence of erectile dysfunction and related health concerns in the general population. Current Medical Research and Opinion 2004 20 5 607 617 2-s2.0-2542438558 10.1185/030079904125003467 (Pubitemid 38685004)
5. Dennerstein L., Koochaki P., Barton I., Graziottin A., Hypoactive sexual desire disorder in menopausal women: a survey of Western European women. Journal of Sexual Medicine 2006 3 2 212 222 2-s2.0-33645974316 10.1111/j.1743-6109. 2006.00215.x
6. Basson R., Rees P., Wang R., Montejo A. L., Incrocci L., Sexual function in chronic illness. Journal of Sexual Medicine 2010 7 1 374 388 2-s2.0-74049128206 10.1111/j.1743-6109.2009.01621.x
7. Angst J., Sexual problems in healthy and depressed persons. International Clinical Psychopharmacology 1998 13 supplement 6 S1 S3
8. Cyranowski J. M., Bromberger J., Youk A., Matthews K., Kravitz H. M., Powell L. H., Lifetime depression history and sexual function in women at midlife. Archives of Sexual Behavior 2004 33 6 539 548 2-s2.0-6044257960 10.1023/B:ASEB.0000044738.84813.3b (Pubitemid 39382623)
9. Hegeman J. M., Kok R. M., van der Mast R. C., Giltay E. J., Phenomenology of depression in older compared with younger adults: meta-analysis. British Journal of Psychiatry 2012 200 275 281 10.1192/bjp.bp.111.095950
10. Lin C. F., Juang Y. Y., Wen J. K., Liu C. Y., Hung C. I., Correlations between sexual dysfunction, depression, anxiety, and somatic symptoms among patients with major depressive disorder. Chang Gung Medical Journal 2012 35 4 323 331
11. Laurent S. M., Simons A. D., Sexual dysfunction in depression and anxiety: conceptualizing sexual dysfunction as part of an internalizing dimension. Clinical Psychology Review 2009 29 7 573 585 2-s2.0-70149089209 10.1016/j.cpr.2009.06.007
12. Vulink N. C. C., Denys D., Bus L., Westenberg H. G. M., Sexual pleasure in women with obsessive-compulsive disorder? Journal of Affective Disorders 2006 91 1 19 25 2-s2.0-32844468925 10.1016/j.jad.2005.12.006 (Pubitemid 43254633)
13. Aksaray G., Yelken B., Kaptanolu C., Oflu S., Özaltin M., Sexuality in women with obsessive compulsive disorder. Journal of Sex and Marital Therapy 2001 27 3 273 277 2-s2.0-0035029220 10.1080/009262301750257128 (Pubitemid 32374399)
14. Williams K., Reynolds M. F., Sexual dysfunction in major depression. CNS Spectrums 2006 11 supplement 9 19 23 2-s2.0-33747720729 (Pubitemid 44273471)
15. Williams V. S. L., Baldwin D. S., Hogue S. L., Fehnel S. E., Hollis K. A., Edin H. M., Estimating the prevalence and impact of antidepressant-induced sexual dysfunction in 2 European countries: a cross-sectional patient survey. Journal of Clinical Psychiatry 2006 67 2 204 210 2-s2.0-33644823990 (Pubitemid 43357465)
16. Williams V. S. L., Edin H. M., Hogue S. L., Fehnel S. E., Baldwin D. S., Prevalence and impact of antidepressant-associated sexual dysfunction in three European countries: replication in a cross-sectional patient survey. Journal of Psychopharmacology 2010 24 4 489 496 2-s2.0-77950391718 10.1177/0269881109102779
17. Serretti A., Chiesa A., Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. Journal of Clinical Psychopharmacology 2009 29 3 259 266 2-s2.0-67649289851 10.1097/JCP.0b013e3181a5233f
18. Gartlehner H., Hansen R. A., Morgan L. C., Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder. An updated meta-analysis. Annals of Internal Medicine 2011 155 11 772 785
19. Demyttenaere K., Jaspers L., Review: bupropion and SSRI-induced side effects. Journal of Psychopharmacology 2008 22 7 792 804 2-s2.0-50249149814 10.1177/0269881107083798
20. Watanabe N., Omori I. M., Nakagawa A., Cipriani A., Barbui C., McGuire H., Churchill R., Furukawa T. A., Mirtazapine versus other anti-depressive agents for depression. Cochrane Database of Systematic Reviews 2007 12 2 2-s2.0-44949095481 10.1002/14651858.CD006528 CD006528 (Pubitemid 351805834)
21. Benelli A., Frigeri C., Bertolini A., Genedani S., Influence of mirtazapine on the sexual behavior of male rats. Psychopharmacology 2004 171 3 250 258 2-s2.0-1042265561 10.1007/s00213-003-1591-y (Pubitemid 38200063)
22. Montejo A. L., Prieto N., Terleira A., Matias J., Alonso S., Paniagua G., Naval S., Parra D. G., Gabriel C., Mocar E., Portolés A., Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale. Journal of Psychopharmacology 2010 24 1 111 120 2-s2.0-76249132673 10.1177/0269881108096507
23. Kennedy S. H., Rizvi S., Fulton K., Rasmussen J., A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. Journal of Clinical Psychopharmacology 2008 28 3 329 333 2-s2.0-51449112441 10.1097/JCP.0b013e318172b48c
24. Hickie I. B., Rogers N. L., Novel melatonin-based therapies: potential advances in the treatment of major depression. The Lancet 2011 378 9791 621 631 10.1016/S0140-6736(11)60095-0
25. Zourkova A., Hadasova E., Paroxetine-induced conversion of cytochrome P450 2D6 phenotype and occurence of adverse effects. General Physiology and Biophysics 2003 22 1 103 113 2-s2.0-0037865865 (Pubitemid 36748384)
26. Zourkova A., Ceskova E., Hadašová E., Ravč uková B., Links among paroxetine-induced sexual dysfunctions, gender, and CYP2D6 activity. Journal of Sex and Marital Therapy 2007 33 4 343 355 2-s2.0-34249889916 10.1080/00926230701385589 (Pubitemid 46868495)
27. Zourkova A., Slanar O., Jarkovsky J., Palcikova I., Pindurova E., Cvanova M., MDR1 in paroxetine-induced sexual dysfunction. Journal of Sex & Marital Therapy 2013 39 1 71 78 10.1080/0092623X.2012.668514
28. Nazareth I., Boynton P., King M., Problems with sexual function in people attending London general practitioners: cross sectional study. British Medical Journal 2003 327 7412 423 426 2-s2.0-0042035612 (Pubitemid 37046786)
29. Read S., King M., Watson J., Sexual dysfunction in primary medical care: prevalence, characteristics and detection by the general practitioner. Journal of Public Health Medicine 1997 19 4 387 391 2-s2.0-0031434871 (Pubitemid 28031265)
30. Rief W., Nestoriuc Y., Von Lilienfeld-Toal A., Dogan I., Schreiber F., Hofmann S. G., Barsky A. J., Avorn J., Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials: a systematic review and meta-analysis. Drug Safety 2009 32 11 1041 1056 2-s2.0-70349972975 10.2165/11316580-000000000-00000
31. Haberfellner E. M., A review of the assessment of antidepressant-induced sexual dysfunction used in randomized, controlled clinical trials. Pharmacopsychiatry 2007 40 5 173 182 2-s2.0-35148817023 10.1055/s-2007-985881 (Pubitemid 47535743)
32. Rizvi S. J., Yeung N. W., Kennedy S. H., Instruments to measure sexual dysfunction in community and psychiatric populations. Journal of Psychosomatic Research 2011 70 1 99 109 2-s2.0-78650570230 10.1016/j.jpsychores.2010.05.009
33. Giuliano F., Hellstrom W. J. G., The pharmacological treatment of premature ejaculation. BJU International 2008 102 6 668 675 2-s2.0-50049129061 10.1111/j.1464-410X.2008.07719.x
34. Fink H. A., MacDonald R., Rutks I. R., Wilt T. J., Trazodone for erectile dysfunction: a systematic review and meta-analysis. BJU International 2003 92 4 441 446 2-s2.0-0041408820 10.1046/j.1464-410X.2003.04358.x (Pubitemid 37100526)
35. Baldwin D., Bridgman K., Buis C., Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine. Journal of Psychopharmacology 2006 20 1 91 96 2-s2.0-33645243454 10.1177/0269881105056666
36. Baldwin D., Moreno R. A., Briley M., Resolution of sexual dysfunction during acute treatment of major depression with milnacipran. Human Psychopharmacology 2008 23 6 527 532 2-s2.0-51049117224 10.1002/hup.955
37. Werneke U., Northey S., Bhugra D., Antidepressants and sexual dysfunction. Acta Psychiatrica Scandinavica 2006 114 6 384 397 2-s2.0-33750738232 10.1111/j.1600-0447.2006.00890.x (Pubitemid 44707066)
38. Hu X. H., Bull S. A., Hunkeler E. M., Ming E., Lee J. Y., Fireman B., Markson L. E., Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate. Journal of Clinical Psychiatry 2004 65 7 959 965 2-s2.0-4444378510 10.4088/JCP.v65n0712
39. Dueñas H., Lee A., Brnabic A. J. M., Chung K. F., Lai C. H., Badr M. G., Uy-Ponio T., Ruiz J. R., Varrey P., Jian H., Dossenbach M., Frequency of treatment-emergent sexual dysfunction and treatment effectiveness during SSRI or duloxetine therapy: 8-week data from a 6-month observational study. International Journal of Psychiatry in Clinical Practice 2011 15 2 80 90 2-s2.0-79955783327 10.3109/13651501.2011.572169
40. Taylor M. J., Rudkin L., Hawton K., Strategies for managing antidepressant-induced sexual dysfunction: systematic review of randomised controlled trials. Journal of Affective Disorders 2005 88 3 241 254 2-s2.0-26844496054 10.1016/j.jad.2005.07.006 (Pubitemid 41446967)
41. Balon R., Segraves R. T., Survey of treatment practices for sexual dysfunction(s) associated with anti-depressants. Journal of Sex and Marital Therapy 2008 34 4 353 365 2-s2.0-46049102191 10.1080/00926230802096390 (Pubitemid 351896796)
42. Rothschild A. J., Selective serotonin reuptake inhibitor-induced sexual dysfunction: efficacy of a drug holiday. American Journal of Psychiatry 1995 152 10 1514 1516 2-s2.0-0029097135
43. Baldwin D. S., Sexual dysfunction associated with antidepressant drugs. Expert Opinion on Drug Safety 2004 3 5 457 470 2-s2.0-4544274763 10.1517/14740338.3.5.457 (Pubitemid 39242720)
44. Amiaz R., Pope H. G., Mahne T., Kelly J. F., Brennan B. P., Kanayama G., Weiser M., Hudson J. I., Seidman S. N., Testosterone gel replacement improves sexual function in depressed men taking serotonergic antidepressants: a randomized, placebo-controlled clinical trial. Journal of Sex and Marital Therapy 2011 37 4 243 254 2-s2.0-79961142027 10.1080/0092623X.2011.582425
45. Nurnberg H. G., Hensley P. L., Gelenberg A. J., Fava M., Lauriello J., Paine S., Treatment of antidepressant-associated sexual dysfunction with sildenafil: a randomized controlled trial. Journal of the American Medical Association 2003 289 1 56 64 2-s2.0-0037221036 10.1001/jama.289.1.56 (Pubitemid 36026278)
46. Nurnberg H. G., Hensley P. L., Heiman J. R., Croft H. A., Debattista C., Paine S., Sildenafil treatment of women with antidepressant-associated sexual dysfunction: a randomized controlled trial. Journal of the American Medical Association 2008 300 4 395 404 2-s2.0-47849090005 10.1001/jama.300.4.395 (Pubitemid 352040251)
47. Segraves R. T., Lee J., Stevenson R., Walker D. J., Wang W. C., Dickson R. A., Tadalafil for treatment of erectile dysfunction in men on antidepressants. Journal of Clinical Psychopharmacology 2007 27 1 62 66 2-s2.0-33846214733 10.1097/jcp.0b013e31802e2d60 (Pubitemid 46105767)
48. Michelson D., Kociban K., Tamura R., Morrison M. F., Mirtazapine, yohimbine or olanzapine augmentation therapy for serotonin reuptake-associated female sexual dysfunction: a randomized, placebo controlled trial. Journal of Psychiatric Research 2002 36 3 147 152 2-s2.0-0036118776 10.1016/S0022-3956(01) 00060-7 (Pubitemid 34218955)
49. Fava M., Dording C. M., Baker R. A., Mankoski R., Tran Q. V., Forbes R. A., Eudicone J. M., Owen R., Berman R. M., Effects of adjunctive aripiprazole on sexual functioning in patients with major depressive disorder and an inadequate response to standard antidepressant monotherapy: a post hoc analysis of 3 randomized, double-blind, placebo-controlled studies. Primary Care Companion to the Journal of Clinical Psychiatry 2011 13 1 e1 e10 2-s2.0-79952778203 10.4088/PCC.10m00994gre
50. Andersson K.-E., Mechanisms of penile erection and basis for pharmacological treatment of erectile dysfunction. Pharmacological Reviews 2011 63 4 811 859 10.1124/pr.111.004515
51. Musicki B., Liu T., Lagoda G. A., Bivalacqua T. J., Strong T. D., Burnett A. L., Endothelial nitric oxide synthase regulation in female genital tract structures. Journal of Sexual Medicine 2009 6 supplement 3 247 253 2-s2.0-61849106062 10.1111/j.1743-6109.2008.01122.x
52. Nurnberg H. G., Seidman S. N., Gelenberg A. J., Fava M., Rosen R., Shabsigh R., Depression, antidepressant therapies, and erectile dysfunction: clinical trials of sildenafil citrate (Viagra) in treated and untreated patients with depression. Urology B 2002 60 supplement 2 58 66 2-s2.0-0036755157 10.1016/S0090-4295(02)01691-6 (Pubitemid 35300147)
53. Rosen R. C., Seidman S. N., Menza M. A., Shabsigh R., Roose S. P., Tseng L. J., Orazem J., Siegel R. L., Quality of life, mood, and sexual function: a path analytic model of treatment effects in men with erectile dysfunction and depressive symptoms. International Journal of Impotence Research 2004 16 4 334 340 2-s2.0-4644359937 10.1038/sj.ijir.3901197 (Pubitemid 39273759)
54. Wegener G., Harvey B. H., Bonefeld B., Müller H. K., Volke V., Overstreet D. H., Elfving B., Increased stress-evoked nitric oxide signalling in the Flinders sensitive line (FSL) rat: a genetic animal model of depression. International Journal of Neuropsychopharmacology 2010 13 4 461 473 2-s2.0-77953529598 10.1017/S1461145709990241
55. Liebenberg N., Harvey B. H., Brand L., Wegener G., Brink C. B., Chronic treatment with the phosphodiesterase type 5 inhibitors sildenafil and tadalafil display anxiolytic effects in Flinders Sensitive Line rats. Metabolic Brain Disease 2012 27 3 337 340 10.1007/s11011-012-9284-z
56. Brink C. B., Clapton J. D., Eagar B. E., Harvey B. H., Appearance of antidepressant-like effect by sildenafil in rats after central muscarinic receptor blockade: evidence from behavioural and neuro-receptor studies. Journal of Neural Transmission 2008 115 1 117 125 2-s2.0-37749000760 10.1007/s00702-007-0806-5
57. Clark S. L., Adkins D. E., Aberg K., Hettema J. M., McClay J. L., Souza R. P., van den Oord E. J., Pharmacogenomic study of side-effects for antidepressant treatment options in STAR D. Psychological Medicine 2012 42 6 1151 1162 10.1017/S003329171100239X
58. Kurose K., Hiratsuka K., Ishiwata K., Genome-wide association study of SSRI/SNRI-induced sexual dysfunction in a Japanese cohort with major depression. Psychiatry Research 2012 198 3 424 429 10.1016/j.psychres.2012.01.023
59. Bishop J. R., Moline J., Ellingrod V. L., Schultz S. K., Clayton A. H., Serotonin 2A -1438 G/A and G-protein beta3 subunit C825T polymorphisms in patients with depression and SSRI-associated sexual side-effects. Neuropsychopharmacology 2006 31 10 2281 2288 2-s2.0-33748766341 10.1038/sj.npp.1301090 (Pubitemid 44413208)
60. Liang C. S., Ho P. S., Chiang K. T., Su HC. 5-HT(2A) receptor -1438 G/A polymorphism and serotonergic antidepressant-induced sexual dysfunction in male patients with major depressive disorder: a prospective exploratory study. Journal of Sexual Medicine. In press
61. Dording C. M., Mischoulon D., Shyu I., Alpert J. E., Papakostas G. I., SAMe and sexual functioning. European Psychiatry 2012 27l 6 451 454 2-s2.0-79952345818 10.1016/j.eurpsy.2011.01.003
62. Dording C. M., Fisher L., Papakostas G., Farabaugh A., Sonawalla S., Fava M., Mischoulon D., A double-blind, randomized, pilot dose-finding study of maca root (L. Meyenii) for the management of SSRI-induced sexual dysfunction. CNS Neuroscience and Therapeutics 2008 14 3 182 191 2-s2.0-49749090475 10.1111/j.1755-5949.2008.00052.x
63. Modabbernia A., Sohrabi H., Nasehi A. A., Raisi F., Saroukhani S., Jamshidi A., Tabrizi M., Ashrafi M., Akhondzadeh S., Effect of saffron on fluoxetine-induced sexual impairment in men: randomized double-blind placebo-controlled trial. Psychopharmacology 2012 223 4 381 388 10.1007/s00213-012-2729-6
64. Norden M. J., Buspirone treatment of sexual dysfunction associated with selective serotonin re-uptake inhibitors. Depression 1994 2 2 109 112 2-s2.0-0028566898
65. Landen M., Erikkson E., Agren H., Fahlen T., Effects of buspirone on sexual function in depressed patients treated with selective serotonin reuptake inhibitors. Journal of Clinical Psychopharmacology 1999 19 3 268 271 10.1097/00004714-199906000-00012 (Pubitemid 29233022)
66. Fabre L. F., Clayton A. H., Smith L. C., Goldstein I., Derogatis L. R., The effect of gepirone-ER in the treatment of sexual dysfunction in depressed men. Journal of Sexual Medicine 2012 9 3 821 829 10.1111/j.1743-6109.2011.02624. x
67. Citrome L., Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant-what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? International Journal of Clinical Practice 2012 66 4 356 368 10.1111/j.1742-1241.2011.02885.x
68. Clayton A. H., Kennedy S. H., Edwards J. B., Gallipoli S., Reed C. R., The effect of vilazodone on sexual function during the treatment of major depressive disorder. Journal of Sexual Medicine. In press 10.1111/jsm.12004
69. Baldwin D. S., Loft H., Dragheim M., A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of LuAA21004 in acute treatment of major depressive disorder (MDD). European Neuropsychopharmacology 2012 22 7 482 491 10.1016/j.euroneuro.2011.11.008
70. Baldwin D., Hutchison J., Donaldson K., Shaw B., Smithers A., Selective serotonin re-uptake inhibitor treatment-emergent sexual dysfunction: randomized double-blind placebo-controlled parallel-group fixed-dose study of a potential adjuvant compound, VML-670. Journal of Psychopharmacology 2008 22 1 55 63 2-s2.0-37749015728 10.1177/0269881107078490
71. Sukoff Rizzo S. J., Pulicicchio C., Malberg J. E., Andree T. H., Stack G. P., Hughes Z. A., Schechter L. E., Rosenzweig-Lipson S., 5-HT1A receptor antagonism reverses and prevents fluoxetine-induced sexual dysfunction in rats. International Journal of Neuropsychopharmacology 2009 12 8 1045 1053 2-s2.0-69749083928 10.1017/S1461145709000406
72. Cipriani A., Furukawa T. A., Salanti G., Geddes P. R., Higgins J. P., Churchill R., Watanabe N., Nakagawa A., Omori I. M., McGuire H., Tansella M., Barbui C., Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. The Lancet 2009 373 9665 746 758 2-s2.0-60849086169 10.1016/S0140-6736(09)60046-5
73. Clayton A. H., Zajecka J., Ferguson J. M., Filipiak-Reisner J. K., Brown M. T., Schwartz G. E., Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder. International Clinical Psychopharmacology 2003 18 3 151 156 2-s2.0-0038402607 10.1097/00004850-200305000-00005 (Pubitemid 36571059)
74. Langworth S., Bodlund O., Ågren H., Efficacy and tolerability of reboxetine compared with citalopram: a double-blind study in patients with major depressive disorder. Journal of Clinical Psychopharmacology 2006 26 2 121 127 2-s2.0-33646691741 10.1097/01.jcp.0000204138.20417.c3 (Pubitemid 43740334)
75. Tran P., Skolnick P., Czobor P., Hunag N. Y., Bradshaw M., McKinney A., Fava M., Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial. Journal of Psychiatric Research 2012 46 1 64 71 10.1016/j.jpsychires.2011.09.003